Natixis’s Arcturus Therapeutics ARCT Stock Holding History

Natixis’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-60	Closed	-$368	–	1112
2025 Q4	$368	Buy	+60	New	+$648	﹤0.01%	1092
2023 Q2	–	Sell	-11,500	Closed	-$276K	–	1021
2023 Q1	$276K	Buy	+11,500	New	+$206K	﹤0.01%	705

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Natixis's ARCT Position: Q1 2026 in Review

Natixis sold out of Arcturus Therapeutics (ARCT) in Q1 2026, closing a stake of 60 shares — an estimated $368 sold.

Natixis first reported a position in ARCT in Q1 2023 and held it in 2 quarters. The position peaked at $276K in Q1 2023. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2026.

Natixis reported no remaining Arcturus Therapeutics position as of Q1 2026 after selling out during the quarter.
Natixis sold 60 Arcturus Therapeutics shares in Q1 2026, an estimated $368.
Natixis first reported a position in Arcturus Therapeutics in Q1 2023 and held it in 2 quarters.
Natixis's Arcturus Therapeutics position peaked at $276K in Q1 2023.
124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.